发明名称 MicromiRs
摘要 The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
申请公布号 US8906871(B2) 申请公布日期 2014.12.09
申请号 US200812681587 申请日期 2008.10.03
申请人 Santaris Pharma A/S 发明人 Obad Susanna;Kauppinen Sakari;Elmén Joacim;Lindow Morten;Heidenblad Markus
分类号 A61K48/00;C12N15/11;C07H21/02;C07H21/04 主分类号 A61K48/00
代理机构 Sterne, Kessler, Goldstein & Fox P.L.L.C. 代理人 Sterne, Kessler, Goldstein & Fox P.L.L.C.
主权项 1. An oligomer of a contiguous sequence of 7, 8, or 9 nucleotide units in length, for use in reducing the effective amount of a microRNA target in a cell or an organism, wherein at least 70% of the nucleotide units of the oligomer are selected from the group consisting of LNA (Locked Nucleic Acid) units and 2′ substituted nucleotide analogues, and wherein at least 50% of the nucleotide units of the oligomer are LNA units, and wherein at least one of the internucleoside linkages present between the nucleotide units of the contiguous nucleotide sequence is a phosphorothioate internucleoside linkage, wherein the contiguous nucleotide sequence is 100% complementary to the seed sequence of miR-21 (SEQ ID NO: 410), and wherein the seed sequence of miR-21 consists of nucleotides 2 to 8 of SEQ ID NO: 410 counting from the sequence's 5′ end.
地址 Hørsholm DK